Literature DB >> 12162505

The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression.

Shreyasee Amin1, Michael P Lavalley, Robert W Simms, David T Felson.   

Abstract

We determined the comparative efficacy of vitamin D, calcitonin, fluoride, and bisphosphonates for the management of corticosteroid-induced osteoporosis using meta-regression models. A systematic search for trials was conducted using MEDLINE, bibliographic references, abstracts from national meetings, and contact with pharmaceutical companies and content experts. We included all randomized controlled trials, lasting at least 6 months, of adult patients on oral corticosteroids that evaluated treatment comparisons between vitamin D, calcitonin, bisphosphonates, or fluoride either with no therapy/calcium or with each other and that reported extractable results. The outcome measure of interest was change in lumbar spine bone mineral density (BMD). We identified 45 eligible trials, which provided 49 eligible treatment comparisons (some trials had three arms or more). Our results indicated that bisphosphonates were the most effective class (effect size 1.03; 95% CI: 0.85, 1.17); results were similar even when newer generations of nitrogen-containing bisphosphonates were excluded from analysis. We found the efficacy of bisphosphonates was enhanced further when used in combination with vitamin D (effect size, 1.31; 95% CI: 1.07, 1.50). Vitamin D and calcitonin were more effective than no therapy/calcium (effect size, 0.46; 95% CI: 0.27, 0.62; and effect size, 0.51; 95% CI: 0.33, 0.67, respectively) and were of similar efficacy, but both were significantly less effective than bisphosphonates. Fluoride appeared effective, but there were too few studies (n = 5) to draw robust conclusions regarding its efficacy compared with the other three therapies. In summary, bisphosphonates are the most effective of evaluated agents for managing corticosteroid-induced osteoporosis. The efficacy of bisphosphonates is enhanced further with concomitant use of vitamin D.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12162505     DOI: 10.1359/jbmr.2002.17.8.1512

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  27 in total

1.  Analysis of bone metabolism during early stage and clinical benefits of early intervention with alendronate in patients with systemic rheumatic diseases treated with high-dose glucocorticoid: Early DIagnosis and Treatment of OsteopoRosis in Japan (EDITOR-J) study.

Authors:  Yoshiya Tanaka; Hiroko Mori; Takatoshi Aoki; Tatsuya Atsumi; Yutaka Kawahito; Hisanori Nakayama; Shigeto Tohma; Yuji Yamanishi; Hitoshi Hasegawa; Kazuhide Tanimura; Nobuo Negoro; Yukitaka Ueki; Atsushi Kawakami; Katsumi Eguchi; Kazuyoshi Saito; Yosuke Okada
Journal:  J Bone Miner Metab       Date:  2015-08-26       Impact factor: 2.626

Review 2.  Glucocorticoid-induced osteoporosis: treatment options and guidelines.

Authors:  Michael Maricic
Journal:  Curr Osteoporos Rep       Date:  2005-03       Impact factor: 5.096

Review 3.  [Particular features of steroid-induced osteoporosis].

Authors:  G E Hein
Journal:  Orthopade       Date:  2007-08       Impact factor: 1.087

Review 4.  Corticosteroid-induced adverse events in adults: frequency, screening and prevention.

Authors:  Laurence Fardet; Abdulrhaman Kassar; Jean Cabane; Antoine Flahault
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

5.  Treatment of glucocorticoid-induced osteoporsis.

Authors:  Gherardo Mazziotti; Andrea Giustina; Ernesto Canalis; John P Bilezikian
Journal:  Ther Adv Musculoskelet Dis       Date:  2009-02       Impact factor: 5.346

Review 6.  Giant cell arteritis: Current treatment and management.

Authors:  Cristina Ponte; Ana Filipa Rodrigues; Lorraine O'Neill; Raashid Ahmed Luqmani
Journal:  World J Clin Cases       Date:  2015-06-16       Impact factor: 1.337

7.  Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update.

Authors:  Yasuo Suzuki; Hajime Nawata; Satoshi Soen; Saeko Fujiwara; Hisanori Nakayama; Ikuko Tanaka; Keiichi Ozono; Akira Sagawa; Ryoichi Takayanagi; Hiroyuki Tanaka; Takami Miki; Naomi Masunari; Yoshiya Tanaka
Journal:  J Bone Miner Metab       Date:  2014-05-13       Impact factor: 2.626

Review 8.  Efficacy of oral etidronate for skeletal diseases in Japan.

Authors:  Jun Iwamoto; Tsuyoshi Takeda; Yoshihiro Sato
Journal:  Yonsei Med J       Date:  2005-06-30       Impact factor: 2.759

Review 9.  Prevention and treatment of corticosteroid-induced osteoporosis.

Authors:  Jun Iwamoto; Tsuyoshi Takeda; Yoshihiro Sato
Journal:  Yonsei Med J       Date:  2005-08-31       Impact factor: 2.759

Review 10.  Long-term therapy in COPD: any evidence of adverse effect on bone?

Authors:  Arnulf Langhammer; Siri Forsmo; Unni Syversen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.